Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960763 · ClinicalTrials.gov registry record · Phase 4
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
A Phase 4 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 742
- Enrollment target
- 5
- Study locations
NCT02960763: Completed Phase 4 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by Washington University School of Medicine.
NCT02960763 is a Phase 4 study of Major Depressive Disorder and Treatment-Resistant Depression that has completed, run by Washington University School of Medicine. The registered enrollment target is 742 participants, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (98% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02960763, a Phase 4 study of Major Depressive Disorder and Treatment-Resistant Depression, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 742 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
Primary Outcome
Psychological well-being was assessed using the NIH Toolbox Psychological Wellbeing subscales of Positive Affect and General Life Satisfaction, with a T score calculated as the average of these two subscales. Higher scores indicate greater positive affect and life satisfaction. Reference T-score (mean=50, SD=10).
Conditions Studied
Interventions
- DRUG Aripiprazole Augmentation
- DRUG Bupropion Augmentation
- DRUG Switch to bupropion
- DRUG Lithium Augmentation
- DRUG Switch to nortriptyline
Study Locations (5)
California
- UCLA Late-Life Mood, Stress, and Wellness Research Program - Los Angeles
Missouri
- Washington University School of Medicine Healthy Mind Lab - St Louis
New York
- Columbia University Adult and Late Life Depression Clinic - New York
Pennsylvania
- UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program - Pittsburgh
Ontario
- Centre for Addiction and Mental Health - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 742 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2021-09-01 |
| Phase | Phase 4 |
What the finished NCT02960763 record still lists
NCT02960763 is an interventional study that assigns participants to a tested intervention. The registered 742 participants enrollment target is mid-sized for trials with a published cap, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (98% higher).
The record links to 5 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 5 interventions - of which Aripiprazole Augmentation is the first listed.
NCT02960763 lists 5 locations in 5 states (California, Missouri, New York).
Frequently Asked Questions
What is clinical trial NCT02960763 about?
NCT02960763 is a clinical study titled "Optimizing Outcomes of Treatment-Resistant Depression in Older Adults". The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
What is the current status of trial NCT02960763?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 742 participants. The study started on 2017-02-24. Estimated completion is 2021-09-01.
What conditions does trial NCT02960763 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Treatment-Resistant Depression, Late Life Depression, Treatment-Refractory Depression, Geriatric Depression.
What interventions are being tested in trial NCT02960763?
The interventions under investigation include: Aripiprazole Augmentation (DRUG), Bupropion Augmentation (DRUG), Switch to bupropion (DRUG), Lithium Augmentation (DRUG), Switch to nortriptyline (DRUG).
Who is sponsoring clinical trial NCT02960763?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02960763 being conducted?
This trial has 5 study locations across California, Missouri, New York, Pennsylvania, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02960763's enrollment target sits among peer trials
742 16th of 282 higher than 267 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
- NCT06556563 · 741 participants · Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI